Lucid Capital analyst Christopher Liu raised the firm’s price target on Lyell Immunopharma (LYEL) to $39 from $32 and keeps a Buy rating on the shares following the fiscal 2025 results. The cites lower estimated dilutive financing this year for the target increase.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma appoints Smital Shah as CFBO
- Lyell Immunopharma initiated with an Outperform at Citizens
- LYEL Earnings this Week: How Will it Perform?
- Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
- Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target